Compare LMAT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | NRIX |
|---|---|---|
| Founded | 1983 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2006 | 2020 |
| Metric | LMAT | NRIX |
|---|---|---|
| Price | $83.45 | $18.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $101.83 | $26.77 |
| AVG Volume (30 Days) | 188.5K | ★ 1.9M |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 27.40 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $240,866,000.00 | $83,687,000.00 |
| Revenue This Year | $15.17 | $58.38 |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $36.21 | ★ N/A |
| Revenue Growth | 13.07 | ★ 48.32 |
| 52 Week Low | $71.42 | $8.18 |
| 52 Week High | $105.55 | $22.50 |
| Indicator | LMAT | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 63.87 |
| Support Level | $82.52 | $19.02 |
| Resistance Level | $85.21 | $22.50 |
| Average True Range (ATR) | 2.32 | 1.20 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 33.21 | 44.60 |
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.